MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 18,146 Shares of Boston Scientific Co. (NYSE:BSX)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 6.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,764 shares of the medical equipment provider's stock after purchasing an additional 18,146 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in Boston Scientific were worth $28,740,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of BSX. Parnassus Investments LLC boosted its position in Boston Scientific by 0.7% during the 4th quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after buying an additional 97 shares during the period. Baldwin Investment Management LLC raised its stake in shares of Boston Scientific by 1.2% during the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock valued at $781,000 after acquiring an additional 102 shares during the last quarter. Evergreen Capital Management LLC lifted its holdings in shares of Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after purchasing an additional 106 shares during the period. PDS Planning Inc lifted its holdings in shares of Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after purchasing an additional 113 shares during the period. Finally, Adero Partners LLC grew its stake in shares of Boston Scientific by 3.3% in the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the sale, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This represents a 19.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares in the company, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 265,820 shares of company stock worth $27,406,958 in the last quarter. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Up 1.1%

Boston Scientific stock traded up $1.14 during mid-day trading on Friday, reaching $106.00. The stock had a trading volume of 7,288,742 shares, compared to its average volume of 6,362,890. The firm has a market capitalization of $156.83 billion, a PE ratio of 84.80, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The stock's 50-day simple moving average is $99.18 and its 200-day simple moving average is $96.66. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter last year, the firm posted $0.56 EPS. Boston Scientific's revenue was up 20.9% compared to the same quarter last year. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Royal Bank of Canada raised their target price on Boston Scientific from $116.00 to $120.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Morgan Stanley raised their price objective on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday. StockNews.com raised Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. BTIG Research reiterated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a report on Wednesday, April 23rd. Finally, Truist Financial raised their price target on shares of Boston Scientific from $113.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday, April 24th. Twenty-three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $114.74.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.